ROEHNRX

Age Verification

This site supplies research compounds for laboratory use only. You must be 21 years of age or older to enter.

By entering you confirm you are 21+ and agree to our Terms of Service. Products are for research use only — not for human consumption.

Your Cart

Your cart is empty

Browse ProductsBrowse Products
Tirzepatide

metabolic-research

Research Use Only

Tirzepatide

4.5 · 2 reviews
Cardiovascular HealthGlycemic ControlNeuroprotectionWeight Management

Tirzepatide is a synthetic peptide that acts as a dual agonist at the GIP and GLP-1 receptors. Examined in pre-clinical and clinical literature for its dual-receptor mechanism and downstream effects on insulinotropic signaling. Sold for laboratory research and identification purposes only. Not for human consumption.

Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.

$189One-time

Quantity

1

Free shipping over $500

HPLC VerifiedPublished COAUSA · Cold-Chain

Paying by Zelle / Apple Cash

New to sending payment this way? It's quick, and your order is protected:

  • Payment confirmed as soon as it lands — usually within minutes during business hours.
  • Most orders ship the same day, cold-packed and discreet.
  • Every order ships tracked, with an email at each step.
  • Questions answered within hours by a real person.

If we ever can't fulfill your order, you're refunded within 1–2 business days.

Tirzepatide

$189

Technical Data

Specifications

Specifications

Technical Details

01
Purity99%+ (HPLC)
02
FormLyophilized Powder
03
StorageStore at -20°C lyophilized. Reconstituted: 2–8°C, use within 28 days.
04
Dosage2.5–15 mg per week in clinical research; preclinical dosing varies by model
05
FormatLyophilized
06
SourceSynthetic
07
Half-Life~5 days
08
MechanismDual GIP/GLP-1 receptor agonist
09
CAS Number2023788-19-2
10
Amino Acids39
11
Molecular Weight4813.45 Da
12
Molecular FormulaC₂₂₅H₃₄₈N₄₈O₆₈

Quality Assurance

Certificate of Analysis

Certificate of Analysis

BatchDL8673
Purity99.5% (HPLC)
Test Date2025-01-29
LabDarmerica (Davie, FL)

Verified Feedback

Reviews

4.5

2 verified reviews

5
1
4
1
3
0
2
0
1
0

2 reviews

Jun 2026

Best customer service I have experienced

The customer support alone deserves five stars. Every question I had was answered quickly, professionally, and thoroughly. Most companies take days to respond, but I consistently received replies within hours, and sometimes even sooner. The team made me feel like an actual person instead of just another order number. Whether I had questions about shipping or product availability, everything was handled immediately. It is rare to find a company that combines excellent service with such a seamless ordering experience. The communication and support have been outstanding, and that is a big reason why I will continue to order from them.

Verified Customer Verified
Feb 2026

Quality products and good prices

Quality products and good prices. Customer service does respond, even if it is a few days late due to possible junk-mail jail.

Timothy Butler· US Verified

Research Overview

About Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism represents a paradigm shift from earlier single-receptor incretin therapies, with clinical evidence suggesting additive or synergistic metabolic effects that exceed what either pathway achieves independently.

The inclusion of GIP receptor agonism targets adipose tissue lipid metabolism, central appetite regulation through pathways distinct from GLP-1, and potentiation of insulin secretion through a separate intracellular signaling cascade. Phase 3 clinical data have reported mean body weight reductions of 15–22% in participants with obesity — positioning tirzepatide among the most effective pharmacological interventions studied for metabolic disease.

ROEHN supplies tirzepatide at 99% HPLC-verified purity as a lyophilized powder. Active research programs continue to explore applications beyond weight management, including non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction, and obstructive sleep apnea — reflecting the broad therapeutic potential of dual incretin receptor modulation.